Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy of Nerve Blocks for Episodic Migraine
Sponsor: Mayo Clinic
Summary
The purpose of this study is to see how well blocking two to ten of the scalp nerves (that give feeling to the scalp and are painful during migraine headaches) with bupivacaine anesthetic (numbing medication) and low dose methylprednisolone (cortisone-like medicine or steroid) work for treating and preventing migraines. Our hypothesis is that the pain of most episodic migraine headaches can be eliminated and prevented for months by blocking the nerves that give pain sensation during a migraine.
Official title: A Randomized Trial of Bilateral Greater Occipital Nerve Blocks Versus Ten Peripheral Nerve Blocks for Acute Relief and Prophylaxis of Episodic Migraine
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2023-07-10
Completion Date
2027-07
Last Updated
2026-06-16
Healthy Volunteers
No
Conditions
Interventions
Bupivacaine HCl 0.5% Injectable Solution
Will receive 0.5 ml (supratrochlear) to 1.0 ml (supraorbital, auriculotemporal) to 1.25 ml (greater and lesser occipital) for each nerve block. Will receive 0.25 ml or 10 mg methylprednisolone to each greater and lesser occipital nerve in the MPNB arm and 0.5 ml or 20 mg methylprednisolone to both greater occipital nerves in the GONB arm.
Methylprednisolone 40 MG Injection
Will receive 10 mg (0.25 ml) mixed with 1.25 ml Bupivacaine 0.5% for each greater and lesser occipital nerve block if MPNB group or 20 mg (0.5 ml) methylprednisolone in each GON if GONB group.
Locations (1)
Mayo Clinic in Rochester
Rochester, Minnesota, United States